



This week in techniques

Summary	Licensing status	information
Modified silica nanoparticles may help detect metastasis in melanoma patients. The nanoparticles consist of polyethylene glycol (PEG), an integrin-targeting peptide and a PET label. In a pig melanoma model, locally injected nanoparticles identified more metastatic sites in the lymph node than the standard PET approach. Ongoing work includes a Phase 0 study looking at the pharmacokinetics, safety and dosimetry of the nanoparticles in metastatic melanoma patients. SciBX 4(26); doi:10.1038/scibx.2011.752	Patent application filed; licensing status undisclosed	Benezra, M. et al. J. Clin. Invest.; published online June 13, 2011; doi:10.1172/JCI45600 Contact: Michelle S. Bradbury, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: bradburm@mskcc.org
	Modified silica nanoparticles may help detect metastasis in melanoma patients. The nanoparticles consist of polyethylene glycol (PEG), an integrin-targeting peptide and a PET label. In a pig melanoma model, locally injected nanoparticles identified more metastatic sites in the lymph node than the standard PET approach. Ongoing work includes a Phase 0 study looking at the pharmacokinetics, safety and dosimetry of the nanoparticles in metastatic melanoma patients.	Modified silica nanoparticles may help detect metastasis in melanoma patients. The nanoparticles consist of polyethylene glycol (PEG), an integrin-targeting peptide and a PET label. In a pig melanoma model, locally injected nanoparticles identified more metastatic sites in the lymph node than the standard PET approach. Ongoing work includes a Phase 0 study looking at the pharmacokinetics, safety and dosimetry of the nanoparticles in metastatic melanoma patients. SciBX 4(26); doi:10.1038/scibx.2011.752